Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks

Antiviral Therapy

Volumn 5, Issue 2, 2000, Pages 95-104

  Korba, Brent E ^a   Cote, Paul ^a   Hornbuckle, William ^b   Schinazi, Raymond ^c   Gangemi, J David ^d   Tennant, Bud C ^b   Gerin, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CLEMSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; LAMIVUDINE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HEPATITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS CARRIER; VIRUS INFECTION; VIRUS REPLICATION; WOODCHUCK;

ANIMALS; ANTIVIRAL AGENTS; CARRIER STATE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; LAMIVUDINE; MARMOTA; RNA, VIRAL; VIREMIA; VIRUS REPLICATION;

EID: 0033868988     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Pillay D, Bartholomeusz A, Cane P, Mutimer D, Schinazi R & Locarnini S. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. International Antiviral News 1998; 6:167-169.
2. Jaeckel E & Manns MP. Experience with lamivudine against hepatitis B virus. Intervirology 1997; 40:322-336.
3. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J & Wu PC. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25:241-244.
4. Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Research 1996; 29:49-51.
5. Perigaud C, Gosselin G, Girardet J-L, Korba B & Imbach J-L. The SATE pronucleotide approach applied to acyclovir. Part I. Synthesis and in vitro anti-HBV activity of bis(SATE)phosphotriester derivatives of acyclovir. Antiviral Research 1999; 40:167-178.